{
    "nct_id": "NCT03219476",
    "official_title": "Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive HER2-Negative Node-Negative Breast Cancer Patients to Assess Responses and Mechanisms of Endocrine Resistance",
    "inclusion_criteria": "* Female; age ≥18 years.\n* Pathologically proven diagnosis of invasive breast cancer, clinically stage I-II.\n* Clinically lymph node negative, confirmed by clinical exam and/or ultrasound imaging.\n* Estrogen- and/or progesterone-receptor-positive tumor, defined ≥1% positively staining cells by immunohistochemistry, according to the current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.\n* HER2/neu must be negative by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH).\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n* Pretreatment evaluations (minimum diagnostic workup) within 28 days prior to study\n* Qualify for anti-endocrine treatment (per medical oncologist).\n* Informed consent provided.\n* If history of contralateral breast cancer, patient completed all treatment two years prior\n* No treatment for this breast cancer or any malignancy within two years (except non-melanomatous skin cancer, carcinoma in situ of the cervix and contralateral breast cancer)\n* Using adequate methods of contraception; negative pregnancy test.\n* No strong CYP2D6 inhibitors.\n* Adequate organ function with baseline lab values.\n\n  * Absolute neutrophil count (ANC) ≥ 1500/µL.\n  * Hemoglobin (Hb) ≥ 9g/dL.\n  * Platelet count ≥ 100,000/µL.\n  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3x upper limit of normal (ULN).\n  * Serum bilirubin within ≤ 1.5 x ULN.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* American Joint Committee on Cancer (AJCC) clinical T4, N1-3 or M1, breast cancer.\n* Synchronous non-breast malignancy (exceptions include non-melanomatous skin cancer, carcinoma in situ of the cervix).\n* Purely noninvasive breast cancer (i.e., ductal carcinoma in situ, lobular carcinoma in situ).\n* Men with breast cancer.\n* Medical, psychiatric or other condition that would prevent the patient from receiving the protocol therapy or providing informed consent.\n* Pregnant or lactating women.",
    "miscellaneous_criteria": ""
}